Metropolitan Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Metropolitan Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$709K	Sell	10,100 -1,300	-11%	-$88.7K	1.41%	17
2015 Q3	$710K	Buy	+11,400	New	+$898K	0.65%	36

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Metropolitan Capital Advisors's XBI Position: Q4 2015 in Review

Metropolitan Capital Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 11% in Q4 2015, selling an estimated $88.7K and leaving 10,100 shares worth $709K. The position accounts for 1.41% of the portfolio, ranked #17.

Metropolitan Capital Advisors first reported a position in XBI in Q3 2015 and has held it in 2 quarters since. The position peaked at $710K in Q3 2015. 199 funds tracked by Wall St. Rank hold XBI as of Q4 2015.

Metropolitan Capital Advisors held 10,100 shares of State Street SPDR S&P Biotech ETF worth $709K as of Q4 2015.
Metropolitan Capital Advisors sold 1,300 State Street SPDR S&P Biotech ETF shares in Q4 2015, an estimated $88.7K.
State Street SPDR S&P Biotech ETF made up 1.41% of Metropolitan Capital Advisors's portfolio in Q4 2015, its #17 holding.
Metropolitan Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and has held it in 2 quarters since.
Metropolitan Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $710K in Q3 2015.
199 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2015.

Based on Metropolitan Capital Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.